When multiple myeloma relapses
RESPOND with a treatment with a tolerable safety profile
KRd adverse events
In the ASPIRE trial there was a longer treatment duration in the KRd arm*
vs the Rd arm (88 vs 57 weeks, respectively).1
AE-related discontinuation rates were similar between KRd and Rd arms.1
- The rate of discontinuations due to AEs was similar in the KRd vs Rd arm – with 15% and 18% discontinuing treatment, respectively.1
- The most common AE leading to discontinuation was pneumonia (1%) in the KRd arm and thrombocytopenia (0.8%) in the Rd arm.1
Refer to Summary of Product Characteristics and Prescribing Information for comprehensive safety information
Frequency of AEs may vary between studies. Refer to SmPC for selected AEs reported in clinical studies.2 *Kyprolis® was given at reduced frequency from cycles 13 to 18 (the day 8 and 9 doses of Kyprolis® were omitted) and discontinued after 18 cycles.1
Please read the SmPC for full comprehensive safety information
- Stewart AK et al. N Engl J Med 2015;372:142–152.
- Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.